Drug intelligence / Profile preview

norpsilocin

Development stage
Unknown
Modality
Small Molecules
Administration
Subcutaneous, Oral, Sublingual, Buccal, Topical, Inhalation, Intravenous, Intramuscular, Transdermal, Intranasal
01

Overview

**Norpsilocin** is a tryptamine alkaloid (C11H14N2O, MW 190.24 g/mol) identified in 2017 in the hallucinogenic mushroom *Psilocybe cubensis*, where it occurs naturally and has been reported as a potential dephosphorylated metabolite of baeocystin. It acts as a near-full **agonist at the 5-HT2A receptor**, exhibiting higher potency than psilocin, with additional affinity for other serotonin receptors; it demonstrates good metabolic stability, blood-brain barrier penetration in animal models, and psychedelic properties associated with tryptamines.[1][5][7][8]

Other names
4-hydroxy-N-methyltryptamine4-HO-NMT3-[2-(methylamino)ethyl]-1H-indol-4-ol
02

Targets

HTR1B (5-Hydroxytryptamine Receptor 1B)HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)HTR7 (5-hydroxytryptamine receptor 7)HRH1 (Histamine H1 Receptor)SIGMAR1 (Sigma non-opioid intracellular receptor 1)TMEM97 (Sigma-2 receptor complex (TMEM97/PGRMC1))

Beyond the preview

Go deeper on norpsilocin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on norpsilocin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call